Specifically, MGMT methylation was seen in 39–53% of CRCs [17, 18], 11% of gastric cancer [19], 30–38% of lung cancer [20, 21], 34–72% of esophageal cancer [22], 34% of soft tissue sarcomas [23], 58% of breast cancer [24], and 30–70% of glioblastoma [25, 26]. Here, MGMT is linked to soft tissue sarcoma.